靶向IL-12与IL-23治疗免疫检查点抑制剂相关不良反应:现状与未来方向
本文为范围综述,系统梳理了接受免疫检查点抑制剂(ICI)的癌症患者中皮肤、风湿、胃肠、内分泌、神经、血液、肾脏及肺等器官免疫相关不良反应(irAE)的发病机制,并汇总了靶向IL-12/23或IL-23抑制剂治疗这些irAE的临床前与临床证据。结论指出,IL-12/23或IL-23阻断对皮肤(银屑病)、风湿(银屑病关节炎)和胃肠(结肠炎)irAE有明确帮助,对肺毒性有潜在应用价值,但尚需更多临床前研究及病例系列积累经验。
要点
- IL-12/23或IL-23阻断对皮肤、风湿和胃肠irAE有明确帮助
- 对ICI相关肺毒性有潜在应用价值
- 需更多临床前研究及病例系列积累IL-23抑制剂经验
核心结论
- IL-12/23或IL-23阻断对皮肤(银屑病)、风湿(银屑病关节炎)和胃肠(结肠炎)irAE有明确帮助,对肺毒性有潜在应用价值。
- 需更多临床前研究识别不同irAE的治疗靶点,并积累IL-23抑制剂用于ICI相关结肠炎和肺炎的病例系列经验。
研究设计与样本
- 范围综述(scoping review),全面检索了接受ICI的癌症患者中多器官irAE发病机制及IL-12/23或IL-23抑制剂治疗的临床前与临床证据。
主要发现
- 不同irAE涉及独特通路,但irAE病理生理学理解仍有限。
- IL-12/23或IL-23阻断在皮肤、风湿和胃肠irAE中有帮助,肺毒性有潜在应用。
临床怎么用
- 可考虑将IL-12/23或IL-23阻断用于皮肤(银屑病)、风湿(银屑病关节炎)和胃肠(结肠炎)irAE。
- 对ICI相关肺毒性可考虑潜在应用IL-12/23或IL-23阻断。
局限性
- 对irAE病理生理学理解有限。
- 在该背景下开展临床试验困难,需更多临床前研究和病例系列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of cancer therapy, but they come with the risk of adverse events that can impact any organ system. Our current knowledge of the mechanisms of these immune-related adverse events (irAEs), as well as suitable treatment options, is limited. Recent studies suggest a role for interleukins 12 (IL-12) and 23 (IL-23) in the pathogenesis of irAEs and a potential role for biologics targeting this axis in their treatment, but specific indications for IL-12 and/or IL-23 blockade are not clear. We reviewed the current evidence for IL-12/23 and IL-23 blockade to treat irAEs in various organ systems. AREAS COVERED: This scoping review comprehensively examined literature on the pathogenesis of cutaneous, rheumatic, gastrointestinal, endocrine, neurologic, hematologic, renal, and pulmonary irAEs in cancer patients receiving ICIs and all preclinical and clinical evidence and rationale for the use of IL-12/23 or IL-23 inhibitors in their treatment. CONCLUSION: Our understanding of the pathophysiology underlying irAEs is limited, but recent studies have shown that unique pathways are involved in different types of irAEs. The use of IL-12/23 or IL-23 blockade is helpful specifically in cutaneous (psoriasis), rheumatic (psoriatic arthritis), and gastrointestinal (colitis) irAEs, and there is potential application in pulmonary toxicity. More preclinical studies are needed to identify therapeutic targets in different irAEs, as well as case series on the clinical experience with these agents in irAEs, especially IL-23 inhibitors for ICI-related colitis and ICI-related pneumonitis, given the difficulty of conducting clinical trials in this context.
引用
- Shatila, Farris, Reid, et al. Targeting IL-12 and IL-23 in immune-related adverse events from checkpoint inhibitors: current evidence and future directions. Eur J Cancer. 2026. PMID: 42950610. doi:10.1016/j.ejca.2026.117788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。